Systemic and local delivery of mesenchymal stem cells for heart renovation: Challenges and innovations

Liu, Ziwei; Mikrani, Reyaj; Zubair, Hafiz Muhammad; Taleb, Abdoh; Naveed, Muhammad; Baig, Mirza Fahad; Zhang, Qin; Li, Cuican; Habib, Murad; Cui, Xingxing; Sembatya, Kiganda Raymond; Han, Lei; Zhou, Xiaohui

doi:10.1016/j.ejphar.2020.173049

Cited by 50 publications

(30 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cell sheet approach is one of the latest strategies for epicardial delivery of the heart utilizing innovative biomedical engineering, which can minimize systemic side effects by targeting delivery. ASD has a similar advantage as a cell sheet, but it can also spread the stem cells or drugs all over the ventricles and deliver cells continuously [38]. Our previous study has confirmed the delivery of lidocaine by ASD was beneficial to reversing calcium chloride-induced ventricular fibrillation [19].…”

Section: Discussionmentioning

confidence: 91%

<strong></strong>Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats

Liu¹,

Naveed²,

Mikrani³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Bone marrow-derived mesenchymal stem cells (BMSCs) have been considered a promising therapeutic approach to cardiovascular disease. This study intends to compare the effect of BMSCs through a standard active cardiac support device (ASD) and intravenous injection on global myocardial injury induced by isoproterenol. BMSCs were cultured in vitro, and the transplanted cells were labeled with a fluorescent dye CM-Dil. Isoproterenol (ISO) was injected into the rats; two weeks later, the labeled cells were transplanted into ISO-induced heart-injury rats through the tail vein or ASD device for five days. The rats were sacrificed on the first day, the third day, and the fifth day after transplantation to observe the distribution of cells in the myocardium by fluorescence microscopy. The hemodynamic indexes of the left ventricle were measured before sacrificing. H&E staining and Masson’s trichrome staining were used to evaluate the cardiac histopathology. In the ASD groups, after three days of transplantation, there were many BMSCs on the epicardial surface, and after five days of transplantation, BMSCs were widely distributed in the ventricular muscle. But in the intravenous injection group, there were no labeled-BMSCs distributed. In the ASD+BMSCs-three days treated group and ASD+BMSCs -five days-treated group, left ventricular systolic pressure (LVSP), the maximum rate of left ventricular pressure rise (+dP/dt), the maximum rate of left ventricular pressure decline (-dP/dt) increased compared with model group and intravenous injection group (P<0.05). By giving BMSCs through ASD device, cells can rapidly and widely distribute in the myocardium and significantly improve heart function.

show abstract

Section: Discussionmentioning

confidence: 91%

<strong></strong>Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats

Liu¹,

Naveed²,

Mikrani³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Systemic delivery is considered a reasonable approach. However, the reported effect in terms of homing rate, survival rate, and maintenance of cellular function was modest and transient [80] for reasons including poor migration rate from vessels to tissues and high retention rate in the liver, lungs, and spleen [81]. In contrast to intravenous delivery, intra-tissue or intraorgan delivery showed higher delivery retention and efficiency, as evidenced by a large body of studies [82].…”

Section: Directed Migratory Capacity Of Mscsmentioning

confidence: 99%

Challenges and advances in clinical applications of mesenchymal stromal cells

et al. 2021

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.

show abstract

“…These materials have been investigated for exhibiting improved treatment efficacy and safety profile compared to the prospects of current diagnostic/treatment options 89–91 . This article overviewed the recent developments in the area of general strategy adaptation of DNA nanostructures interface with the biology and proposing solutions to many of the current challenges 92–94 . DNA nanostructured self‐assembly and functional optimization open the horizon to biochemical and biomedical applications.…”

Section: Summary and Outlooksmentioning

confidence: 99%

Development and functionalization of DNA nanostructures for biomedical applications

Zou

Neelakantan

Zhang

2021

J Chinese Chemical Soc

View full text Add to dashboard Cite

Nanomaterials are excellent drug delivery systems, yet, they must be functionalized in a manner compatible with the biological environment. Regarding delivery of the payloads, it is critical to monitor the nanocarrier's biocompatibility and the ability to control its drug encapsulation and release, as well as targeting. The current challenges include avoiding negative host immune responses, optimizing stability in biological environments, and achieving precise interactions with the targets. Contemporary advances in structural DNA nanotechnology, DNA origami, and supramolecular DNA assembly make it possible to produce complex multi‐functional DNA nanostructures, wherein precise control of the size, geometry, and appearance of the ligands is feasible. DNA nanostructures offer ease of synthesis and conjugation of functional moieties to target the release of cargo or to analyze important biomarkers for diagnostics. Furthermore, the biocompatibility, programmability, responsiveness to biomolecules, cell‐surfaces, and organisms make such DNA nanomaterials highly suitable for potential translational applications. This overview summarizes the recent developments in functionalizing, stabilizing, and applying DNA nanostructures for potential biomedical applications.

show abstract

Systemic and local delivery of mesenchymal stem cells for heart renovation: Challenges and innovations

Cited by 50 publications

References 123 publications

<strong></strong>Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats

<strong></strong>Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats

Challenges and advances in clinical applications of mesenchymal stromal cells

Development and functionalization of DNA nanostructures for biomedical applications

Contact Info

Product

Resources

About